New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
NCT ID NCT04781088
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors more effectively than current options, while monitoring side effects. About 38 participants will receive the drugs to evaluate safety and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15224, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells retrained to hunt ovarian cancer in new trial
- Hormone blocker plus targeted drug shows promise against tough uterine cancer
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches